Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cue Biopharma

CUE
Current price
3.09 USD -0.01 USD (-0.32%)
Last closed 2.92 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 108 295 928 USD
Yield for 12 month -1.59 %
Week
Month
Year
CUE
21.11.2021 - 28.11.2021

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139

Analytics

WallStreet Target Price

10.25 USD

P/E ratio

Dividend Yield

Current Year

+1 245 227 USD

Last Year

+14 941 370 USD

Current Quarter

+2 100 000 USD

Last Quarter

+1 382 000 USD

Current Year

+1 245 227 USD

Last Year

+14 941 370 USD

Current Quarter

+2 100 000 USD

Last Quarter

+1 382 000 USD

Key Figures CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -52 555 224 USD
Operating Margin TTM -543.76 %
PE Ratio
Return On Assets TTM -45.8 %
PEG Ratio
Return On Equity TTM -111.08 %
Wall Street Target Price 10.25 USD
Revenue TTM 3 820 227 USD
Book Value 0.95 USD
Revenue Per Share TTM 0.087 USD
Dividend Share
Quarterly Revenue Growth YOY 2988.2 %
Dividend Yield
Gross Profit TTM 1 245 227 USD
Earnings Share -1.2 USD
Diluted Eps TTM -1.2 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CUE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 18.2597
Price Sales TTM 28.348
Enterprise Value EBITDA -1.4646
Price Book MRQ 2.5329

Financials CUE

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CUE

For 52 weeks

1.7 USD 5.12 USD
50 Day MA 2.19 USD
Shares Short Prior Month 3 110 983
200 Day MA 3.19 USD
Short Ratio 9.48
Shares Short 3 027 838
Short Percent 6.93 %